Artificial Intelligence
Datametrex Obtains Rights to Sell COVID-19 Tests From Two Additional South Korean Manufacturers
TORONTO, May 06, 2020 (GLOBE NEWSWIRE) — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that it has secured non-exclusive rights to sell COVID-19 test kits from two additional South Korean manufacturers, including a kit that is U.S. Food & Drug Administration (“FDA”) approved under Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices (“EUA”) for the United States, and CE marking certification (“CE”) for European Economic Area (“EEA”) countries, which covers the 27 member states of the EU, the 4 members of EFTA, plus Turkey and the United Kingdom under Brexit.According to each of the manufacturers, these test kits made are both Nucleic Acid based, which Health Canada is prioritizing the review of. Each of the manufacturers’ test kits have been submitted to Health Canada approval on a fast track basis and, until such approval is granted, these tests may not be sold or used in Canada. The Company is currently working closely with Health Canada to have the approval of the test kits fast tracked. An Interim Order Request for Health Canada has been submitted for 300,000 kits immediately and an additional 100,000 weekly thereafter.One of the test kits, manufactured by Seasun Biomaterials (“Seasun”) Inc. of South Korea, was authorized on April 27, 2020 by the FDA in the United States for Emergency Use under the EUA by authorized laboratories and has also been approved for use in the EEA with CE marking certification. With regard to the FDA authorization: (1) this test has not been FDA cleared or approved; (2) this test has been authorized by the FDA only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and (3) this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.Seasun claims that the average number of specimens that can be tested in a 12 hour period with their U-TOP COVID-19 Real-Time Detection Kit is 3,400. Seasun advises this is the equivalent of approximately 283 tests per hour, and the kit uses dual-labeled peptide nucleic acid probes to detect two distinct regions in ORF1ab and one region in N gene of the SARS-CoV-2 genome in oropharyngeal and nasopharyngeal swab specimens, anterior nasal and mid-turbinate nasal swabs, nasopharyngeal wash/aspirate or nasal aspirate specimens, and sputum. The test runs on any authorized RT-PCR instrument and can be performed by any lab CLIA-certified to perform high-complexity tests.Seasun is an in vitro diagnostic company that develops molecular diagnostic platforms of infection diseases, cancer as well as genetic and epigenetic disorders. Seasun develops and commercializes innovative real-time PCR-based diagnostic platforms through the development of its proprietary technologies to provide more advanced molecular diagnostic services. Seasun’s test kits will be distributed by its third party distributor, which Datametrex has agreements in place with for distribution globally. The other manufacturer that Datametrex has obtained sales rights from has requested not to be named publicly at this time.The Company announced on April 21, 2020 the appointments of Dr. Joseph Curtis and Dr. Lisa Palleson-Stallan to the advisory board in anticipation of securing US FDA EUA approval on the test kits. Selling into the US market requires infrastructure and a qualified contact person that can assist not only in identifying opportunities to sell the test kits but also with the compliance requirements. The Company is continuing to work with Health Canada with respect to the application for approval of previously announced iONEBIO Inc. COVID-19 test kits.“Having seen the urgent need for COVID-19 test kits, Datametrex is doing everything it can to help Canada combat COVID-19 and flatten the curve. In the meantime, having FDA under EUA approved test kits allow us to help our neighbours to the south and any Canadian company with operations in the US and Europe,” says Marshall Gunter, CEO of the Company.The Company’s ability to fulfill any purchase order for COVID-19 test kits is subject to the availability of inventory at the time of order. Due to the extraordinarily high demand for COVID-19 test, there is volatility in the supply chain and available supply may fluctuate on a daily basis. Datametrex anticipates that it will have little or no upfront costs associated with importing and selling these test kits. Assuming Health Canada approves the test kits and they are subsequently purchased by the Canadian government, the manufacturer will ship the test kits directly to the Canadian government or hospitals, and Datametrex will not be involved in the shipping, warehousing or distribution process.The Company did not pay consideration to either of the manufacturers to obtain sales rights. Seasun’s application to have its test approved by Health Canada were submitted directly by Seasun, while Datametrex submitted an application for approval with respect to the other manufacturer’s tests.About CE MarkingCE marking is a certification mark that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area (EEA). The CE marking is also found on products sold outside the EEA that have been manufactured to EEA standards. This makes the CE marking recognizable worldwide even to people who are not familiar with the European Economic Area (the 27 member states of the EU, the 4 members of European Free Trade Association (“EFTA”), plus Turkey and United Kingdom). CE marking also supports fair competition by holding all companies accountable to the same rules. For more information please consult the European Commission website at: CE marking.About Food and Drug Administration EUAOn February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act.About DatametrexDatametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Additional information on Datametrex is available at www.datametrex.com.For further information, please contact:Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]Jeff Stevens – Advisor
Phone: (647) 400-8494
Email: [email protected]Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking StatementsThis news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
PARIS, June 17, 2024 /PRNewswire/ — MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced the collaboration with SeqOne, a leading provider of AI-driven genomic decision support software, to develop and validate end-to-end genomic analysis solutions from sample to report tailored to the needs of Human Genetics and Pathology labs worldwide.
This collaboration between MGI and SeqOne encompasses three distinct initiatives:
Validating an end-to-end, automated, cost-effective solution for HRD signature with MGI DNBSEQ-G99
The collaboration between a Pathology Reference Lab in Spain, Agilent Technologies, MGI, and SeqOne aims to technically validate a routine workflow leveraging Agilent panels, Magnis lib prep automation, MGI DNBSEQ-G99, and SeqOne somaHRD, a clinically validated HRD signature solution, on 96 samples.
This end-to-end solution for pathology molecular labs will enable high-quality, efficient, and flexible HRD testing worldwide, including Genomic Instability score and BRCA testing.
Enabling and validating SeqOne tertiary analysis solution compatible with MGI Megabolt for Germline Panels, Whole Exome and Whole Genome
MegaBOLT bioinformatics analysis accelerator, self-developed and MPS-concentrated hardware accelerating system by MGI, is set to ensure seamless integration and compatibility with SeqOne’s AI-powered variants identification and analysis solution.
The collaboration aims to combine MegaBOLT and the SeqOne Platform to deliver a versatile, cost-effective, intuitive, and time-saving solution from sample to report, particularly attractive for high-throughput Human Genetics labs.
Validating SeqOne CE-IVD Platform for Germline and Somatic analysis for use with MGI sequencers in routine diagnostics
This technical validation project aims to evaluate the compatibility of the SeqOne Platform with MGI sequencing data. It will validate variant calling performances on a set of reference control samples in terms of QC, sensitivity and precision.
“We are thrilled to announce our collaboration with SeqOne. By combining MGI’s cutting-edge sequencing technology with SeqOne’s innovative genomic analysis Platform, we are poised to deliver real insights and solutions for personalized healthcare,” said Dr. Yong Hou, General Manager of MGI Europe and Africa. “This collaboration underscores our commitment to advancing genomic research and providing clinicians with the tools they need to offer tailored treatments to their patients.”
“This partnership with MGI strongly supports SeqOne’s mission to broaden access to sophisticated genomic analysis, aiming to improve healthcare outcomes,” said Martin Dubuc, CEO, SeqOne. “Molecular laboratories globally are exploring how MGI’s sequencing and bioinformatics technologies can advance next-generation sequencing (NGS) research and diagnostics. We are eager to integrate SeqOne’s CE-IVD Platform with MGI’s offerings, enhancing the quality, sensitivity, and precision of bioinformatic analyses.”
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.
About SeqOne
SeqOne is a fast-growing deep-tech company focused on turning genomic data into medically- actionable insights in oncology and rare and inherited diseases. Our vision is to make personalized healthcare a reality for every patient, everywhere. We are committed to democratizing access to advanced genomic insights, enabling labs of any size, in any location, to offer affordable personalized medicine solutions to patients at scale. We integrate cutting-edge AI and big data technologies to redefine genetic data analysis. Our CE-IVD Platform provides time saving, flexible, and cost-effective decision support, empowering decentralized laboratories worldwide to deliver precision diagnostics.The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club. To learn more, please visit www.seqone.com and Linkedin.
Logo – https://mma.prnewswire.com/media/2329841/MGI__Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/mgi-tech-and-seqone-partner-to-advance-end-to-end-genomic-analysis-302173987.html
Artificial Intelligence
Symphony Talent’s Award-Winning Full-Funnel Talent Acquisition Portfolio Earns Strategic Challenger Status on Fosway 9-Grid™ for Third Consecutive Year
NEW YORK and LONDON, June 17, 2024 /PRNewswire/ — Symphony Talent, a global leader in recruitment marketing technology and employer brand services, has been named a Strategic Challenger on the 2024 Fosway 9-Grid™ for Talent Acquisition for the third consecutive year, demonstrating Symphony Talent’s consistent dedication to providing cutting-edge solutions that drive game-changing results for talent acquisition teams worldwide.
“From rapidly evolving technologies to shifting candidate expectations, the TA industry faces many challenges,” says Sven Elbert, Head of Analyst Services at Fosway Group. “A full-funnel talent acquisition solution — that seamlessly aligns employer branding, technology and data analytics to the candidate journey — is essential to address these complexities. Symphony Talent provides a robust framework for meeting the diverse needs of complex, global enterprise-scale clients.”
Empowering TA Teams with Full-Funnel Solutions
Symphony Talent’s extensive portfolio of talent acquisition solutions, including its Brand and Creative Services, Programmatic Media Advertising, Career Sites, CRM, and Assessments, drive outstanding client results by addressing every stage of the talent acquisition funnel. Over 700 global clients leverage Symphony Talent’s innovative technologies and strategic expertise, achieving significant outcomes, such as:
Cutting administrative recruiting tasks by 65%Spending 70% less time managing media spendReducing time spent qualifying talent by 60%Decreasing cost per hire by 25%Filling open positions 30% fasterEnsuring quality hires with a 15% reduction in employee turnover”We are honored to be recognized as a Strategic Challenger on the Fosway 9-Grid™ for the third year in a row,” says Kermit Randa, CEO of Symphony Talent. “This achievement highlights our ongoing commitment to connect clients with innovative, high-impact solutions and data that empower them to navigate the complexities of today’s talent landscape and confidently convert candidates to co-workers.”
Highlights of Symphony Talent’s Achievement:
Innovation and Leadership: Symphony Talent’s continuous recognition as a Strategic Challenger is a testament to its unwavering commitment to innovation and leadership in the talent acquisition industry. The company’s comprehensive suite of solutions, including the award-winning SFX platform, integrates brand and creative services with recruitment marketing technology to streamline the hiring process and enhance candidate experience.Client-Centric Approach: Symphony Talent’s focus on understanding and addressing its clients’ evolving needs has been pivotal in maintaining its strategic position. Symphony Talent ensures clients achieve tangible and measurable outcomes by offering personalized support, detailed implementation schedules, and optimization workgroups.Adaptation to Market Trends: With a deep understanding of the current market dynamics and the challenges faced by talent acquisition teams, Symphony Talent has continuously adapted its offerings to meet these demands. This includes leveraging AI and automation to enhance productivity and providing data-driven insights to optimize recruitment strategies.About the Fosway 9-Grid™
Fosway Group is Europe’s #1 HR industry analyst. The Fosway 9-Grid™ provides a unique assessment of the principal learning and talent supply options available to organisations in EMEA. The analysis is based on extensive independent research and insights from Fosway’s Corporate Research Network of over 250 organisations, including BP, HSBC, PwC, RBS, Sanofi, Shell, and Vodafone. Visit the Fosway website at www.fosway.com.
About Symphony Talent
Symphony Talent is a recruitment marketing technology and employer brand services company that helps talent acquisition teams execute strategic, innovative candidate interactions. Our award-winning, synergistic technology and brand solutions are designed to deliver outcomes — from reach to retention — that unlock a competitive advantage for clients across the globe, including the world’s leading brands. Visit symphonytalent.com to learn more.
Logo – https://mma.prnewswire.com/media/2287879/ST_Logo_Single_Line_Full_Color__12_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/symphony-talents-award-winning-full-funnel-talent-acquisition-portfolio-earns-strategic-challenger-status-on-fosway-9-grid-for-third-consecutive-year-302173377.html
Artificial Intelligence
Darwinbox named as a Customers’ Choice in the 2024 Gartner® Peer Insights™ Voice of the Customer for Cloud HCM Suites Report for Enterprises with 1,000+ Employees
DUBAI, UAE, June 17, 2024 /PRNewswire/ — Darwinbox, a global leader in cloud-based HCM solutions, today announced that it has been distinguished as a Customers’ Choice in the 2024 Gartner® Peer Insights™ Voice of the Customer for Cloud HCM Suites for 1,000+ Employee Enterprises.
The Gartner® Peer Insights™ Customers’ Choice distinction is based on feedback and ratings from end-user professionals with experience using the product or service. As of 31 January 2024, Darwinbox received an overall rating of 4.8 out of 5 stars across 141 reviews.
“We believe this distinction, for the third consecutive year, reflects our unwavering commitment to our customers and their success, as well as our dedication to excellence and innovation in the HCM space,” says Jayant Paleti, co-founder, Darwinbox.
Darwinbox has been named a Customers’ Choice for both Large Enterprise (1B – 10B USD) and Midsize Enterprise (50M – 1B USD) segments, showcasing its robust capabilities in handling large-scale operations and its widespread appeal across various business sizes. This recognition underscores the platform’s popularity, driven by its powerful configurability, intuitive design, and agility. An impressive 98% of customers rated Darwinbox 4-stars or higher, highlighting the overwhelming satisfaction with the product.
Furthermore, Darwinbox is recognized as the most customer-friendly enterprise-grade HCM solution globally. The platform distinguishes itself through its ease of implementation and integration, prompt vendor responses, and exceptional technical support, demonstrating Darwinbox’s dedication to quick service and client satisfaction. Notably, 94% of its customers have expressed their willingness to recommend Darwinbox, demonstrating its significant impact and reliability in the enterprise tech landscape.
“What I love is when we need support, the customer service is top-notch – always responsive, solution makers, and always helpful,” HR Business Partner, Media Industry
“Darwinbox has been able to cater to our needs given our diverse business structures and differences in processes,” HR Lead, Manufacturing Sector
Read more reviews
About Darwinbox:
Darwinbox is a leading SaaS-based HR technology platform, empowering organisations to automate HR processes and elevate the employee experience. Rated the highest globally among HCM players on Gartner’s customer review platform, Peer Insights, Darwinbox is trusted by 900+ global enterprises with more than 2.5 million employees spread across 116+ countries.
Photo: https://mma.prnewswire.com/media/2438686/Darwinbox_Voice_of_the_Customer.jpg
View original content:https://www.prnewswire.co.uk/news-releases/darwinbox-named-as-a-customers-choice-in-the-2024-gartner-peer-insights-voice-of-the-customer-for-cloud-hcm-suites-report-for-enterprises-with-1-000-employees-302173015.html
-
Artificial Intelligence7 days agoADP Rings NASDAQ Opening Bell Celebrates 75 Years at the Forefront of Payroll & HR Innovation
-
Artificial Intelligence7 days agoTraceLink Partners with Genpact to Expand Delivery of Digital Supply Chain Innovation for Healthcare and Life Sciences Sectors
-
Artificial Intelligence3 days agoBorderless AI & Cohere team up to build a custom-trained AI model for HR professionals, taking on Deel and Remote.com
-
Artificial Intelligence7 days agoEmpowering data practitioners will help shape generative AI deployment for enterprise, says new MIT Technology Review Insights research report
-
Uncategorized6 days agoHughes Europe Expands into Military, Defence & Government Sectors with Launch of Konnect VHTS Services in Collaboration with Telespazio
-
Uncategorized4 days ago
AI Could Transform UK’s Public Finances as Labour Touts Gains
-
Artificial Intelligence3 days agoLoRa and LoRaWAN IoT Market worth $32.7 billion by 2029- Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence3 days ago
Complyport’s new AI tool – ViCA.Chat – set to revolutionise compliance support services
